Loos, a professor at the University of Copenhagen and affiliated with a research center supported by the Novo Nordisk Foundation (the maker of Wegovy and Ozempic), noted, "The current model explains only 25% of the variability, and further research is needed to uncover the remaining 75%." However, she also expressed optimism, stating, "By combining genetic and clinical information, the era of personalized medicine, where we can select the best drug for each patient, may be upon us."
Nuclei in the mediobasal hypothalamus respond to signals from peripheral energy stores to adjust energy consumption to maintain a normal ratio of lean body to adipose mass
Identification of a central role for complement in osteoarthritis
Current evidence does not establish a direct pharmacological mechanism by which semaglutide would alter mood, though indirect factors such as blood glucose changes or gastrointestinal symptoms may influence emotional wellbeing